Virus like particles as immunogens and universal nanocarriers

Polish Journal of Microbiology

Volumn 64, Issue 1, 2015, Pages 3-13

  Naskalska, Antonina ^a   Pyrć, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Delivery platform; Vaccines; Virus like particles (VLPs)

Indexed keywords

ANTIGEN; BLEOMYCIN; CARBOXYFLUORESCEIN; DOXORUBICIN; HEPATITIS B VACCINE; HEPATITIS E VACCINE; INFLUENZA VACCINE; METAL NANOPARTICLE; NANOCARRIER; NUCLEIC ACID; PROPIDIUM IODIDE; QUANTUM DOT; RECOMBINANT HEPATITIS B VACCINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; NANOMATERIAL; RECOMBINANT VACCINE;

B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; ENCAPSULATION; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOGENICITY; INFECTION; NONHUMAN; REVIEW; VIRION; VIRUS GENOME; VIRUS LIKE AGENT; ANIMAL; GENE VECTOR; VIRUS;

ANIMALS; GENETIC VECTORS; HUMANS; NANOSTRUCTURES; VACCINES, SYNTHETIC; VIRUSES;

EID: 84926368675     PISSN: 17331331     EISSN: 25444646     Source Type: Journal    
DOI: 10.33073/pjm-2015-001     Document Type: Review

References (104)

1. Acosta-Rivero N., J.C. Aguilar, A. Musacchio, V. Falcón, A. Viña, M.C. de la Rosa and J. Morales. 2001. Characterization of the HCV core virus-like particles produced in the methylotrophic yeast Pichia pastoris. Biochem. Biophys. Res. Commun. 287: 122-125.
2. Aden D.P., A. Fogel, S. Plotkin, I.Damjanov and B.B. Knowles. 1979. Controlled synthesis of HBsAg in a diferentiated human liver carcinoma-derived cell line. Nature 282: 615-616.
3. Agnandji S.T.L.B., J.F. Fernandes, B.P. Abossolo, B.G. Methogo, A.L. Kabwende, A.A. Adegnika, B. Mordmuller, S. Issifou, P.G. Kremsner, J. Sacarlal, P. Aide, M. Lanaspa, J.J. Aponte, S. Machevo, S. Acacio, H. Bulo, B. Sigauque, E. Macete, P. Alonso, S. Abdulla, N. Salim, R. Minja, M. Mpina, S. Ahmed, A.M. Ali, A.T. Mtoro, A.S. Hamad, P. Mutani, M. Tanner, H. Tinto, U. d'Alessandro, H. Sorgho and others. 2012. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367: 2284-2295.
4. Aires K.A., A.M. Cianciarullo, S.M. Carneiro, L.L. Villa, E. Boccardo, G. Pérez-Martinez, I. Perez-Arellano, M.L. Oliveira and P.L. Ho. 2006. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl. Environ.Microbiol. 72: 745-752.
5. Akahata W., Z.Y. Yang, H. Andersen, S. Sun, H.A. Holdaway, W.P. Kong, M.G. Lewis, S. Higgs, M.G. Rossmann, S. Rao and others. 2010. A virus-like particle vaccine for epidemic Chikungu-nya virus protects nonhuman primates against infection. Nat. Med. 16: 334-338.
6. Almeida J.D., D.C.Edwards, C.M. Brand and T.D. Heath. 1975. Formation of virosomes from infuenza subunits and liposomes. Lancet 2: 899-901.
7. Bachmann M.F. and G.T. Jennings. 2011. Terapeutic vaccines for chronic diseases: successes and technical challenges. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366: 2815-2822.
8. Barrett P.N., W. Mundt, O. Kistner and M.K. Howard. 2009. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8: 607-618.
9. Baumert T.F., S. Ito, D.T. Wong and T.J. Liang. 1998. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J.Virol. 72: 3827-3836.
10. Bergsdorf C., C. Beyer, V. Umansky, M. Werr and M. Sapp M. 2003. Highly efficient transport of carboxyfuorescein diacetate suc-cinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett. 536: 120-124.
11. Betenbaugh M., M. Yu, K. Kuehl, J. White, D. Pennock, K. Spik and C. Schmaljohn. 1995. Nucleocapsid-and virus-like particles assemble in cells infected with recombinant baculoviruses or vac-cinia viruses expressing the M and the S segments of Hantaan virus. Virus Res. 38: 111-124.
12. Braun M., C. Jandus, P. Maurer, A. Hammann-Haenni, K. Schwarz, M.F Bachmann, D.E. Speiser and P. Romero. 2012. Virus-like par-ticles induce robust human T-helper cell responses. Eur. J. Immunol. 42: 330-340.
13. Buonaguro L., M. Tagliamonte, M.L. Tornesello and F.M. Buona-guro. 2011. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev.Vaccines 10: 1569-1583.
14. Chackerian B., D.R. Lowy and J.T. Schiller. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108: 415-423.
15. Chackerian B., M. Rangel, Z. Hunter and D.S. Peabody. 2006. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 24: 6321-6331.
16. Chandramouli S., A. Medina-Selby, D. Coit, M. Schaefer, T. Spencer, L.A. Brito, P. Zhang, G. Otten, C.W. Mandl, P.W. Mason and others. 2013. Generation of a parvovirus B19 vaccine candidate. Vaccine 31: 3872-3878.
17. Chang G.J., A.R. Hunt, D.A.Holmes, T. Springfield, T.S. Chiueh, J.T. Roehrig and D.J. Gubler. 2003. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306: 170-180.
18. Charpilienne A., M. Nejmeddine, M. Berois, N. Parez, E. Neumann, E. Hewat, G. Trugnan and J. Cohen. 2001. Individual rota-virus-like particles containing 120 molecules of fuorescent protein are visible in living cells. J. Biol. Chem. 276: 29361-29367.
19. Chroboczek J., I. Szurgot and E. Szolajska. 2014. Virus-like par-ticles as vaccine. Acta Biochim. Pol. 61: 531-539.
20. Deleré Y., O. Wichmann, S.J. Klug, M. van der Sande, M. Ter-hardt, F. Zepp and T. Harder. 2014. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch. Arztebl. Int. 111: 584-591.
21. Denis J., N. Majeau, E. Acosta-Ramirez, C. Savard, M.C. Bedard, S. Simard, K. Lecours, M. Bolduc, C. Pare, B. Willems and others. 2007. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 363: 59-68.
22. El-Kamary S.S., M.F. Pasetti, P.M. Mendelman, S.F. Frey, D.I. Bernstein, J.J. Treanor, J. Ferreira, W.H. Chen, R. Sublett, C. Richardson and others. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202: 1649-1658.
23. Fender P., G. Schoehn, J. Foucaud-Gamen, E. Gout, A. Garcel, E. Drouet and J. Chroboczek. 2003. Adenovirus dodecahedron allows large multimeric protein transduction in human cells. J. Virol. 77: 4960-4964.
24. Fuschiotti P., P. Fender, G. Schoehn and J.F. Conway. 2006. Devel-opment of the dodecahedral penton particle from adenovirus 3 for therapeutic application. J. Gen. Virol. 87: 2901-2905.
25. Garcel A., E. Gout, J. Timmins, J. Chroboczek and P. Fender. 2006. Protein transduction into human cells by adenovirus dodeca-hedron using WW domains as universal adaptors. J. Gene. Med. 8: 524-531.
26. Gerber S., C. Lane, D.M. Brown, E. Lord, M. DiLorenzo, J.D. Clements, E. Rybicki, A.L. Williamson and R.C. Rose. 2001. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75: 4752-4760.
27. Gheysen D., E. Jacobs, F. de Foresta, C. Tiriart, M. Francotte, D. Tines and M. De Wilde. 1989. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovi-rus-infected insect cells. Cell 59: 103-112.
28. Gleiter S. and H. Lilie. 2003. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol. Chem. 384: 247-255.
29. Glenn G.M., G. Smith, L. Fries, R. Raghunandan, H. Lu, B. Zhou, D.N. Tomas, S.P. Hickman, E. Kpamegan, S. Boddapati and others. 2013. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31: 524-532.
30. Goldmann C., N. Stolte, T. Nisslein, G. Hunsmann, W. Lüke and H. Petry. 2000. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J. Virol. Methods 90: 85-90.
31. Greco R., M. Michel, D. Guetard, M. Cervantes-Gonzalez, N. Pelucchi, S.Wain-Hobson, F. Sala and M. Sala. 2007. Produc-tion of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. Vaccine 25: 8228-8240.
32. Grgacic E.V. and D.A. Anderson. 2006. Virus-like particles: pass-port to immune recognition. Methods 40: 60-65.
33. Groothuis T.A. and J. Neefes. 2005. The many roads to cross-presentation. J. Exp. Med. 202: 1313-1318.
34. Hanumantha Rao N., P. Baji Babu, L. Rajendra, R. Sriraman, Y.Y. Pang, J.T. Schiller and V.A. Srinivasan. 2011. Expression of codon optimized major capsid protein (L1) of human papillomavi-rus type 16 and 18 in Pichia pastoris; purification and characteriza-tion of the virus-like particles. Vaccine 29: 7326-7334.
35. Harper D.M., E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N.S. De Carvalho and others. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765.
36. Herbst-Kralovetz M., H.S. Mason and Q. Chen Q. 2010. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9: 299-307.
37. Hjelm B.E., J. Kilbourne and M.M. Herbst-Kralovetz. 2014. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum. Vaccin. Immunother. 10: 410-416.
38. Jain A. and S.K. Jain. 2008. PEGylation: an approach for drug deliv-ery. A review. Crit. Rev. Ter. Drug Carrier Syst. 25: 403-447.
39. Juarez V., H.A. Pasolli, A. Hellwig, N. Garbi and A.C. Arregui. 2012. Virus-like particles harboring CCL19, IL-2 and HPV16 E7 elicit protective T cell responses in HLA-A2 transgenic mice. Open Virol. J. 6: 270-276.
40. Kang S.M., Q. Yao, L. Guo and R.W. Compans. 2003. Mucosal immunization with virus-like particles of simian immunodefi-ciency virus conjugated with cholera toxin subunit B. J. Virol. 77:9823-9830.
41. Kazaks A., R. Balmaks, T. Voronkova, V. Ose and P. Pumpens. 2008. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol. J. 3: 1429-1436.
42. Keller S.A., K. Schwarz, V. Manolova, C.E. von Allmen, M.G. Kinzler, M. Bauer, S. Muntwiler, P. Saudan and M.F. Bach-mann. 2010. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur. J. Immunol. 40: 103-112.
43. Kimchi-Sarfaty C., M. Arora, Z. Sandalon, A. Oppenheim and M.M. Gottesman. 2003. High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum.Gene. Ter. 14: 167-177.
44. Kitai Y., H. Fukuda, T. Enomoto, Y. Asakawa, T. Suzuki, S. Inouye and H. Handa. 2011. Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor. J. Biotech-nol. 155: 251-256.
45. Kolesnikova L., B. Berghöfer, S. Bamberg and S. Becker. 2004. Multivesicular bodies as a platform for formation of the Marburg virus envelope. J. Virol. 78: 12277-12287.
46. Kushnir N., S.J. Streatfield and V. Yusibov. 2012. Virus-like par-ticles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31: 58-83.
47. Lee Y.T., K.H. Kim, E.J. Ko, Y.N. Lee, M.C. Kim, Y.M. Kwon, Y. Tang, M.K. Cho, Y.J. Lee and S.M. Kang. 2014. New vaccines against infuenza virus. Clin. Exp. Vaccine Res. 3: 12-28.
48. Li T.C., J. Zhang, H. Shinzawa, M. Ishibashi, M. Sata, E.E. Mast, K. Kim, T. Miyamura and N. Takeda. 2000. Empty virus-like par-ticle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J. Med. Virol. 62: 327-333.
49. Liu F., S. Ge, L. Li, X.Wu, Z. Liu and Z. Wang. 2012. Virus-like particles: potential veterinary vaccine immunogens. Res. Vet. Sci. 93: 553-559.
50. Liu F., X. Wu, L. Li, Z. Liu and Z. Wang. 2013. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr. Purif.90: 104-116.
51. Liu Y.V., M.J. Massare, D.L. Barnard, T. Kort, M. Nathan, L. Wang and G. Smith. 2011. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and infuenza matrix 1 effi-ciently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29: 6606-6613.
52. Ludwig C. and R. Wagner. 2007. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 18: 537-545.
53. Lünsdorf H., C. Gurramkonda, A. Adnan, N. Khanna and U. Rinas. 2011. Virus-like particle production with yeast: ultra-structural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen. Microb. Cell Fact 10: 48.
54. Malboeuf C.M., D.A. Simon, Y.E. Lee, H.A. Lankes, S. Dewhurst, J.G. Frelinger and R.C. Rose. 2007. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 25: 3270-3276.
55. Manolova V., A. Flace, M. Bauer, K. Schwarz, P. Saudan and M.F. Bachmann. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38: 1404-1413.
56. Mason H.S., D.M. Lam and C.J. Arntzen. 1992. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA 89: 11745-11749.
57. Mateu M.G. 2011. Virus engineering: functionalization and stabi-lization. Protein Eng. Des. Sel. 24: 53-63.
58. Maurer P., G.T. Jennings, J. Willers, F. Rohner, Y. Lindman, K. Roubicek, W.A. Renner, P. Müller and M.F. Bachmann. 2005. A therapeutic vaccine for nicotine dependence: preclinical effi-cacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35: 2031-2040.
59. May T., S. Gleiter and H. Lilie. 2002. Assessment of cell type spe-cific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J. Virol. Methods 105: 147-157.
60. McGinnes L.W., H. Pantua, J.P. Laliberte, K.A. Gravel, S. Jain and T.G. Morrison. 2010. Assembly and biological and immunologi-cal properties of Newcastle disease virus-like particles. J. Virol. 84: 4513-4523.
61. Morein B., A. Helenius, K. Simons and V. Schirrmacher. 1979. Virus spike protein complexes and virosomes as effective subunit vaccines. Adv. Exp. Med. Biol. 114: 811-816.
62. Oh Y.K., T. Sohn, J.S. Park, M.J. Kang, H.G. Choi, J.A. Kim, W.K. Kim, J.J. Ko and C.K. Kim. 2004. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology 328: 266-273.
63. Pan Y., T. Jia, Y. Zhang, K. Zhang, R. Zhang, J. Li and L. Wang. 2012. MS2 VLP-based delivery of microRNA-146a inhibits auto-antibody production in lupus-prone mice. Int. J. Nanomedicine 7: 5957-5967.
64. Pattenden L.K., A.P. Middelberg, M. Niebert and D.I. Lipin. 2005. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23: 523-529.
65. Petry H., C. Goldmann, O. Ast and W. Lüke. 2003. The use of virus-like particles for gene transfer. Curr. Opin. Mol. Ter. 5: 524-528.
66. Petukhova N.V., T.V. Gasanova, P.A. Ivanov and J.G. Atabekov. 2014. High-level systemic expression of conserved infuenza epitope in plants on the surface of rod-shaped chimeric particles. Viruses 6: 1789-1800.
67. Phelps J.P., N. Dang and L. Rasochova. 2007. Inactivation and puri-fication of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J.Virol. Methods 141: 146-153.
68. Pniewski T. 2012. Is an oral plant-based vaccine against hepatitis B virus possible? Curr. Pharm. Biotechnol.13: 2692-2704.
69. Pushko P., P. Pumpens and E. Grens. 2013. Development of virus-like particle technology from small highly symmetric to large com-plex virus-like particle structures. Intervirology 56: 141-165.
70. Pushko P., T.M. Tumpey, F. Bu, J. Knell, R. Robinson and G. Smith. 2005. Infuenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 infuenza virus induce protective immune responses in BALB/c mice. Vaccine 23: 5751-5759.
71. Quan F.S., Y. Kim, S. Lee, H. Yi, S.M. Kang, J. Bozja, M.L. Moore and R.W. Compans. 2011. Viruslike particle vaccine induces protec-tion against respiratory syncytial virus infection in mice. J. Infect. Dis. 204: 987-995.
72. Ramqvist T., K. Andreasson and T. Dalianis. 2007. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin. Biol. Ter. 7: 997-1007.
73. Reperant L.A., G.F. Rimmelzwaan and A.D. Osterhaus. 2014. Advances in infuenza vaccination. F1000Prime Rep 6: 47.
74. Rodríguez-Limas W.A., K.E. Tyo, J. Nielsen, O.T. Ramírez and L.A. Palomares. 2011. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb. Cell Fact. 10: 33.
75. Roldão A., M.C. Mellado, L.R. Castilho, M.J. Carrondo and P.M. Alves. 2010. Virus-like particles in vaccine development. Expert Rev. Vaccines 9: 1149-1176.
76. Rosales-Mendoza S., N. Rubio-Infante, D.O. Govea-Alonso and L. Moreno-Fierros. 2012. Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Rep. 31: 495-511.
77. Roy P. and R. Noad. 2008. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin 4: 5-12.
78. Rychlowska M., B. Gromadzka, K. Bienkowska-Szewczyk and B. Szewczyk. 2011. Application of baculovirus-insect cell expression system for human therapy. Curr. Pharm. Biotechnol. 12: 1840-1849.
79. Sakuragi S., T. Goto, K. Sano and Y. Morikawa. 2002. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 99: 7956-7961.
80. Sällberg M., J. Hughes, J. Jones, T.R. Phillips and D.R. Milich. 2002. A malaria vaccine candidate based on a hepatitis B virus core platform. Intervirology 45: 350-361.
81. Sánchez-Rodríguez S.P., L. Münch-Anguiano, O. Echeverría, G. Vázquez-Nin, M. Mora-Pale, J.S. Dordick and I. Bustos-Jaimes. 2012. Human parvovirus B19 virus-like particles: In vitro assembly and stability. Biochimie 94: 870-878.
82. Scotti N. and E.P. Rybicki. 2013. Virus-like particles produced in plants as potential vaccines. Expert Rev. Vaccines 12: 211-224.
83. Senti G., P. Johansen, S. Haug, C. Bull, C. Gottschaller, P. Mül-ler, T. Pfister, P. Maurer, M.F. Bachmann, N. Graf and others. 2009. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 39: 562-570.
84. Seo H.S., J.S. Park, K.Y. Han, K.D. Bae, S.J. Ahn, H.A. Kang and J. Lee. 2008. Analysis and characterization of hepatitis B vaccine partic-les synthesized from Hansenula polymorpha. Vaccine 26: 4138-4144.
85. Seow Y. and M.J. Wood. 2009. Biological gene delivery vehicles: beyond viral vectors. Mol. Ter. 17: 767-777.
86. Shen L., J. Zhou, Y. Wang, N. Kang, X. Ke, S. Bi and L. Ren. 2014. Efficient encapsulation of Fe3 O4 nanoparticles into genetically engineered hepatitis B core virus-like particles through a specific interaction for potential bioapplications. Small
87. Soulié J.C., P. Devillier, J. Santarelli, A. Goudeau, P. Vermeulen, M. Guellier, P. Saliou, A. M. Hillion, F. Tron and J. Huchet. 1991. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine 9: 545-548.
88. Takehara K., D. Ireland and D.H. Bishop. 1988. Co-expression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors. J. Gen. Virol. 69 (Pt 11): 2763-2777.
89. Tang Y.X., L.F. Jiang, J.M. Zhou, Y. Yin, X.M. Yang, W.Q. Liu and D.Y. Fang. 2012. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris. Chin. Med. J. (Engl) 125: 1986-1992.
90. Tissot A.C., P. Maurer, J. Nussberger, R. Sabat, T. Pfister, S. Ignatenko, H.D. Volk, H. Stocker, P. Müller, G.T. Jennings and others. 2008. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827.
91. Tissot A.C., R. Renhofa, N. Schmitz, I. Cielens, E. Meijerink, V. Ose, G.T. Jennings, P. Saudan, P. Pumpens and M.F. Bachmann. 2010. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 5: e9809.
92. Tomé-Amat J., L. Fleischer, S.A. Parker, C. Bardliving and C. Batt. 2014. Secreted production of assembled Norovirus virus-like par-ticles from Pichia pastoris. Microb. Cell Fact. 13: 134.
93. Valenzuela P., A. Medina, W.J. Rutter, G. Ammerer and B.D. Hall. 1982. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 347-350.
94. Wojta-Stremayr D. and W.F. Pickl. 2013. Fluorosomes: fuorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions. Sensors (Basel) 13: 8722-8749.
95. Woo M.K., J.M. An, J.D. Kim, S.N. Park and H.J. Kim. 2008. Expression and purification of human papillomavirus 18 L1 virus-like particle from saccharomyces cerevisiae. Arch.Pharm. Res. 31: 205-209.
96. Wu L., L. Jiang, Z. Zhou, J. Fan, Q. Zhang, H. Zhu, Q. Han and Z. Xu. 2003. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 21: 4390-4398.
97. Yamayoshi S. and Y. Kawaoka. 2007. Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. J. Infect. Dis. 196 Suppl 2: S291-295.
98. Yusibov V., D.C. Hooper, S.V. Spitsin, N. Fleysh, R.B. Kean, T. Mikheeva, D. Deka, A. Karasev, S. Cox, J. Randall and others. 2002. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20: 3155-3164.
99. Zeltins A. 2013. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53: 92-107.
100. Zeng C.Q., M. Labbé, J. Cohen, B.V. Prasad, D. Chen, R.F. Ramig and M.K. Estes. 1994. Characterization of rotavirus VP2 particles. Virology 201: 55-65.
101. Zhao Q., W. Chen, Y. Chen, L. Zhang, J. Zhang and Z. Zhang. 2011. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug. Chem. 22: 346-352.
102. Zochowska M., A. Paca, G Schoehn, J.P. Andrieu, J. Chroboczek, B. Dublet. and E. Szolajska. 2009. Adenovirus dodecahedron, as a drug delivery vector. PLoS One 4: e5569.
103. Zuckerman A.J. 1980. Prophylaxis of hepatitis type B: immunoglobulins and vaccines. Clin Gastroenterol 9: 65-83.
104. Zuckerman A.J. 1985. Subunit, recombinant and synthetic hepatitis B vaccines. Microbiol. Sci. 2: 129-130, 133-128.